Maturity-onset diabetes and nephropathy

  • Catharine I. Whiteside
Part of the Developments in Nephrology book series (DINE, volume 34)


Kidney disease associated with diabetes mellitus is now the number one cause of end-stage renal failure (ESRF) in North America [1]. Non-insulindependent diabetes mellitus (NIDDM) patients over 60 years of age constitute the majority of those diabetics entering dialysis programs [2, 3]. Unlike insulin-dependent diabetes mellitus (IDDM), NIDDM shows more clear-cut, racial predispositions to progressive nephropathy [4]. This paper outlines the risk factors, current concepts about disease mechanisms, diagnosis and therapeutic strategies.


Diabetic Nephropathy Macrovascular Disease NIDDM Patient Persistent Proteinuria Mesangial Expansion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hostetter TH. Diabetic Nephropathy. In: Brenner BM and Rector FC, editors. The Kidney, Vol. II. Philadelphia: Saunders, 1986; 1377–1402.Google Scholar
  2. 2.
    Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: Effect of rare and type II diabetes mellitus. Am J Kidney Dis 1989; 13:485–493.PubMedGoogle Scholar
  3. 3.
    Canadian Organ Replacement Register 1990. Preliminary statistics on renal failure and solid organ transplantation in Canada. Presented at the 24th Annual Meeting of the Canadian Society of Nephrology and the Canadian Transplant Society, September 20–23, 1991. Quebec. Fenton SSA and Jeffery J, editors, Hospital Medical Records Institute.Google Scholar
  4. 4.
    Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and Type II diabetes mellitus. Am J Kidney Dis 1989; 13:485–493.PubMedGoogle Scholar
  5. 5.
    Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci (USA) 1984; 81:583–587.CrossRefGoogle Scholar
  6. 6.
    Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, Cerami A. Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages: A model for turnover of aging cells. J Exp Med 1987; 156:539–549.CrossRefGoogle Scholar
  7. 7.
    Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174:931–939.PubMedCrossRefGoogle Scholar
  8. 8.
    Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170:1387–1407.PubMedCrossRefGoogle Scholar
  9. 9.
    Shultz PJ, Dicorleto PE, Silver BJ, Abboud HE. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 1988; 255:F674–F684.PubMedGoogle Scholar
  10. 10.
    Vlassara H, Brownlee M, Manogue KR, Dinarello C and Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 1988; 240:1546–1548.PubMedCrossRefGoogle Scholar
  11. 11.
    Sedor JR, Nakazato Y, Konieczkowski M. Interleukin-1 and the mesangial cell. Kidney Int 1992; 41:595–599.PubMedCrossRefGoogle Scholar
  12. 12.
    Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 1988; 33:917–924.PubMedCrossRefGoogle Scholar
  13. 13.
    Soulis-Liparota T, Cooper M, Papazoglou P, Clarke B, Jerums G. Retardation by amino-guanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in Streptozotocin-induced diabetic rats. Diabetes 1991; 40:1328–1334.PubMedCrossRefGoogle Scholar
  14. 14.
    Davies PF, Remuzzi A, Gordon E. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci (USA) 1986; 83:2114–2117.CrossRefGoogle Scholar
  15. 15.
    Abboud HE. Platelet-derived growth factor and mesangial cells. Kidney Int 1992; 41:581–583.PubMedCrossRefGoogle Scholar
  16. 16.
    Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1984; 19:410–415.CrossRefGoogle Scholar
  17. 17.
    Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke H, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925–1930.PubMedCrossRefGoogle Scholar
  18. 18.
    Rennke HG, Sandstrom S, Zatz R, Meyer TW, Cowan RS, Brenner BM. The role of dietary protein in the development of glomerular structural alterations in long-term experimental diabetes mellitus. Kidney Int 1986; 29:289 (Abstr).Google Scholar
  19. 19.
    Kasiske BL, O’Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33:667–672.PubMedCrossRefGoogle Scholar
  20. 20.
    Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH. Incidence of nephropathy in type 2 diabetes mellitus in the Pima Indians. Kidney Int 1989; 35:681–687.PubMedCrossRefGoogle Scholar
  21. 21.
    Greene DA, Lattimer SA, Sima AAF. Pathogenesis and prevention of diabetic neuropathy. Diabetes/Metabolism Rev 1988; 4:201–221.CrossRefGoogle Scholar
  22. 22.
    Winegrad A. Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36:396–406.PubMedGoogle Scholar
  23. 23.
    Gillon KRW, Hawthorne JN, Tomlinson DR. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibition. Diabetologia 1983; 25:365–371.PubMedCrossRefGoogle Scholar
  24. 24.
    Greene DA, DeJesus PV, Winegrad Al. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute STZ diabetes. J Clin Invest 1975; 55:1326–1336.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee T-S, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci (USA) 1989; 86:5141–5145.CrossRefGoogle Scholar
  26. 26.
    Pfeilschifter J. Regulatory functions of protein kinase C in glomerular mesangial cells. Klin Wochenschr 1990; 68:1134–1137.PubMedCrossRefGoogle Scholar
  27. 27.
    Kashgarian M, Sterzel RB. The pathobiology of the mesangium. Kidney Int 1992; 41:524–529.PubMedCrossRefGoogle Scholar
  28. 28.
    Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol (Renal Fluid Electrolyte Physiol. 30) 1991; 261:F571–F578.Google Scholar
  29. 29.
    Viberti GC, Jarrett RJ, Mahmud U, Hill RD, Argyropoulos AK, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1:1430–1432.PubMedCrossRefGoogle Scholar
  30. 30.
    Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356–360.PubMedCrossRefGoogle Scholar
  31. 31.
    Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt DJ, Moffett CD, Teutsch SM, Bennett PH. Incidence of end-stage renal disease in Type 2 (non-insulindependent) diabetes mellitus in Pima Indians. Diabetologia 1988; 31:730–736.PubMedCrossRefGoogle Scholar
  32. 32.
    Glassock RJ, Hirschman GH, Striker GE. Workshop on the use of renal biopsy in research on diabetic nephropathy: A summary report. Am J Kidney Dis 1991; 18:589–592.PubMedGoogle Scholar
  33. 33.
    Ballard DJ, Humphrey LL, Melton LJ III, Frohnert PP, Chu C-P, O’Fallon WM, Palumbo PJ. Epidemiology of persistent proteinuria in Type II diabetes mellitus: population-based study in Rochester, Minnesota. Diabetes 1988; 37:405–412.PubMedCrossRefGoogle Scholar
  34. 34.
    Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320:1161–1165.PubMedCrossRefGoogle Scholar
  35. 35.
    Krolewski AS, Canessa M, Warram JH, Laffel LMB, Christlieb AR, Knowler WC, Rand LI. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988; 318:140–145.PubMedCrossRefGoogle Scholar
  36. 36.
    Cowie CC, Port F, Wolff RA, Savage PJ, Moll DP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321:1074–1079.PubMedCrossRefGoogle Scholar
  37. 37.
    Pugh JA, Stern MP, Haffner SM, Eifler CW, Zapata M. Excess incidence of treatment of end-stage renal disease in Mexican-Americans. Am J Epidemiol 1988; 127:135–144.PubMedGoogle Scholar
  38. 38.
    Young TK, Kaufert JM, McKenzie JKI, Hawkins A, O’Neil J. Excessive burden of end-stage renal disease among Canadian Indians: A national survey. Am J Public Health 1989; 79:756–758.PubMedCrossRefGoogle Scholar
  39. 39.
    Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL. Pettitt MJ, Moffet CD, Teutsch SM, Bennett PH. Incidence of end-stage renal disease in type 2 (non-insulindependent) diabetic mellitus in Pima Indians. Diabetologia 1988; 31:730–736.PubMedCrossRefGoogle Scholar
  40. 40.
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia 1989; 2:219–226.CrossRefGoogle Scholar
  41. 41.
    Bosch JP, Lew S, Glabman S, Lauer A. Renal hemodynamic changes in humans: Response to protein loading in normal and diseased kidneys. Am J Med 1986; 81:809–815.PubMedCrossRefGoogle Scholar
  42. 42.
    University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes - VII Evaluation of insulin therapy: final report. Diabetes 1982; 31(suppl 5):1–81.Google Scholar
  43. 43.
    Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 1992; 41:912–919.PubMedCrossRefGoogle Scholar
  44. 44.
    Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Int Med 1990; 113:987–988.PubMedGoogle Scholar
  45. 45.
    Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Int Med 1990; 112:707–708.PubMedGoogle Scholar
  46. 46.
    Baba T, Murabayashi S, Takebe K. Comparison of the renal effect of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomized controlled trial. Diabetologia 1989; 32:40–44.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • Catharine I. Whiteside

There are no affiliations available

Personalised recommendations